Together, these data point to the acute leukemia cells’ TP53 status—a key marker for the sensitivity of both AML and B-ALL to conventional chemotherapy [25,26,27,28]—as a biomarker for patient selection or, in clinical drug testing, patient stratification when CLM-based ADCs are used. This evidence concerns the gene TP53 and acute lymphoblastic leukemia.